Last checked at 4 Dec 2019 11:50
MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics
MaxCyte Shares Rise As It Signs Development Deal With KSQ Therapeutics
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
MaxCyte Share News (MXCT)
MXCT Share
Price
MXCT Share
News
MXCT Share
Chat
MXCT Share
Trades
MXCT
Live RNS
MXCT Share
Charts
MXCT Level 2
Console
MXCT Live
Share Price
MXCT Broker
Ratings
MXCT Directors
Deals
MXCT Financial
Diary
MXCT
Fundamentals
MXCT Short
Positions
MXCT
Media
MaxCyte Information
Share Price Information for MaxCyte (MXCT)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
295.00
Bid:
0.00
Ask:
0.00
Change:
0.00 (0.00%)
Spread:
10.00 (3.448%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
295.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.21 Nov 2019 18:55
MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma
MaxCyte Inks Non-Exclusive Licence Agreement With Vor Biopharma
Read more21 Nov 2019 16:40
MaxCyte strikes deal with oncology company Vor Biopharma
(Sharecast News) - Cell-based therapies and life sciences company MaxCyte announced a clinical and commercial licence agreement with oncology company Vor Biopharma on Thursday, under which Vor would use MaxCyte's 'Flow Electroporation' technology to produce engineered hematopoietic stem cells (eHSCs), and initiate investigational new drug-enabling studies to accelerate its progress towards the clinic.
Read more24 Oct 2019 12:53
MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11
MaxCyte Advances Phase I Clinical Trial Of Cancer Drug MCY-M11
Read more7 Oct 2019 12:23
MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included
MaxCyte And Editas Ink Five Medicine Licence Deal, EDIT-301 Included
Read more18 Sep 2019 11:59
MaxCyte Interim Rises Revenue But Loss Widens On CARMA Investment
(Alliance News) - Life sciences company MaxCyte Inc on Wednesday reported first half revenue growth but its loss widened as expenses soared.In the six months to June 30, the firm's rose
Read more11 Sep 2019 16:04
UK Earnings, Trading Statements Calendar - Next 7 Days
Thursday 12 September WM Morrison SupermarketsHalf Year ResultsBrooks MacdonaldFull Year
Read more17 Jul 2019 13:43
MaxCyte Progresses On MCY-M11 Development As Interim Revenue Rises
(Alliance News) - MaxCyte Inc on Wednesday reported double-digit revenue growth in the first half of 2019 and expects to see continued progress throughout the second half of the year.The is
Read more26 May 2019 21:53
Sunday share tips: IQE, MaxCyte
(Sharecast News) - In his 'Inside the City' column for The Sunday Times, Ben Woods looked at the effect of Donald Trump's posturing against Huawei on the chipmaking industry - particularly, wafer semiconductor technology minnow IQE.
Read more8 May 2019 15:58
MaxCyte begins dosing second cohort in MCY-M11 clinical trial
(Sharecast News) - Clinical-stage, cell-based therapies and life sciences company MaxCyte has initiated dosing for the second cohort of patients in its US phase 1 clinical trial with MCY-M11 - the lead, wholly-owned, non-viral mRNA-based cell therapy candidate from its CARMA platform - it announced on Wednesday.
Read more8 May 2019 12:11
MaxCyte Dosing Second Patients Group In Phase One Cancer Drug Trial
LONDON (Alliance News) - MaxCyte Inc on Wednesday said it has begun dosing for the second cohort of patients in its phase one trial of cancer drug MCY-M11.Shares in MaxCyte were down 5.7% a
Read more24 Apr 2019 11:37
MaxCyte Outlook Confident As Loss Narrows In 2018 On Higher Revenue
LONDON (Alliance News) - MaxCyte Inc on Wednesday said its loss narrowed in 2018 on higher annual fees from its partners as it progresses on MCY-M11 therapeutic candidate development.The a
Read more17 Apr 2019 16:06
UK Earnings, Trading Statements Calendar - Next 7 Days
Thursday 18 April UnileverQ1 ResultsPZ CussonsTrading SolutionsTrading 19 events
Read more8 Apr 2019 13:58
MaxCyte Launches ExPERT Cellular Engineering Technology Platform
LONDON (Alliance News) - MaxCyte Inc on Monday announced the launch of its new ExPERT technology platform for use in cellular engineering.MaxCyte also noted that its business had produced
Read more8 Apr 2019 08:34
MaxCyte launches new generation of cellular engineering instruments
(Sharecast News) - MaxCyte on Monday launched its ExPERT technology platform, a family of instruments that are the next generation of its complex cellular engineering technology.
Read more